Download free PDF
Hydrogels for 3D Bioprinting Market - By Hydrogel Type, By Bioprinting Technology, By Application, By End Use - Growth Forecast, 2025 - 2034
Report ID: GMI14950
|
Published Date: October 2025
|
Report Format: PDF
Download Free PDF
Authors: Kiran Pulidindi, Kavita Yadav
Premium Report Details
Base Year: 2024
Companies covered: 20
Tables & Figures: 150
Countries covered: 22
Pages: 210
Download Free PDF
Hydrogels for 3D Bioprinting Market
Get a free sample of this report
Get a free sample of this report Hydrogels for 3D Bioprinting Market
Is your requirement urgent? Please give us your business email
for a speedy delivery!

Hydrogels for 3D Bioprinting Market Size
The global hydrogels for 3D bioprinting market was estimated at USD 275 million in 2024. It is expected to grow from USD 335.6 million in 2025 to USD 886.4 million by 2034, at a CAGR of 11.4% according to latest report published by Global Market Insights Inc.
6.5%
Collective market share in 2024 is Collective Market Share 35.5 %
Hydrogels for 3D Bioprinting Market Trends
Hydrogels for 3D Bioprinting Market Analysis
Based on hydrogel type, the market is segmented into natural hydrogels, synthetic hydrogel, hybrid systems. Natural hydrogels hold a market value of USD 168.2 million in 2024.
Based on bioprinting technology, the hydrogels for 3D bioprinting market is segmented into extrusion-based bioprinting, droplet-based bioprinting, laser-assisted bioprinting, stereolithography & light-based and emerging technology. Extrusion-Based Bioprinting segment was valued at USD 140.7 million in 2024.
Based on applications, the hydrogels for 3D bioprinting market is segmented into tissue engineering & regenerative medicine, drug delivery systems, disease modeling & drug discovery, biosensors & diagnostics & others. Tissue engineering & regenerative medicine segment was valued at 70% share in 2024.
Based on end-user, the hydrogels for 3D bioprinting market is segmented into pharmaceutical, biotechnology, academic & research institutions, clinical & healthcare providers & others. Pharmaceutical segment was valued at USD 113.1 million in 2024.
The U.S. hydrogels for 3D bioprinting market accounted for USD 99.3 million in 2024. U.S. plays a strategic role in the hydrogels market, favorably geared towards 3D bioprinting due to its strong research infrastructure, an advanced biotech industry, and significant investments in regenerative medicine. North America is benefiting from collaborative partnerships with academic institutions, pharmaceutical companies, and startups to unlock their potential hydrogel formulations that aim to improve bioprinting accuracy and cell viability. Furthermore, the ongoing demand for personalized medicine and an increasingly favorable regulatory environment will drive the adoption of hydrogel-based bioprinting technologies in North America, thus elevating the importance of the region in the global forward ecosystem of tissue engineering and regenerative applications.
The hydrogels for 3D bioprinting market in Europe is witnessing innovations driven strongly due to eco-sustainable material development. The region gives emphasis on developing eco-friendly and biodegradable hydrogels, which are in line with the wider European priority of environmental responsibilities and circular economy principles. Europe further enjoys a diversified network of specialized biotech clusters and collaborative projects funded by the European Union designed to advance the field of bio-printing in regenerative medicine and complex tissue fabrication. Rising healthcare demand and aging populations contributes to the steady growth and the positioning of Europe as a hub for specialized hydrogel technologies in 3D bioprinting.
Asia Pacific currently has a rapidly growing segment in the hydrogels for 3D bioprinting market as investments expand across biotechnology and healthcare infrastructures in the countries of China, Japan, and South Korea. The region benefits from skilled researchers to flourish, while government initiatives to promote advanced healthcare technology have also been registered. Further rapid demand for affordable and effective regenerative treatments coupled with a growing pharmaceutical and research industry is speeding up the uptake of hydrogel-based bioprinting solutions.
The Latin American hydrogels for 3D bioprinting market is growing as research institutions and biotech companies in the region explore home-grown potentials in developing new biomaterials. This development in the market is further increased by collaboration of universities and private sector players geared toward the development of cost-effective hydrogels that meet some of the most pressing healthcare challenges in the region. The government initiatives are aimed at improving the healthcare infrastructure and developing advanced manufacturing technologies provide a conducive environment for advancements in bioprinting.
The Middle East and Africa has now become a promising region for hydrogels for 3D bioprinting market due to increased investments in advanced healthcare technologies and research initiatives in tissue engineering and regenerative medicine. Demand for personalized medical treatment whereby the health-care system is transformed to adapt itself more efficiently through government support policies can encourage the adoption of 3D bioprinting technology in countries like the UAE, Saudi, and South Africa. In addition, partnerships between local research institutions and the world's biotech companies are fast-tracking the generation of new hydrogel materials for bioprinting purposes, thus ensuring steady growth in this market in the region.
Hydrogels for 3D Bioprinting Market Share
The global market are moderately concentrated, with the top five players having market share of 35.5%, with the market leader being Cellink AB (BICO Group), which holds a 6.5% market share.
Hydrogels for 3D Bioprinting Market Companies
Major players operating in the hydrogels for 3D bioprinting industry include:
Cellink AB (BICO Group) Cellink AB is a part of the BICO Group which is basically a biotechnology company specializing in 3D bioprinting technologies, including bioinks, bioprinters, and lab related tools that are used in life sciences and tissue engineering. It is originally focused on developing bioprinting which are more accessible through ready-to-use bioinks. The company has since expanded into broader areas such as lab automation and human tissue modeling. By integrating biology with engineering, it supports research in drug development, regenerative medicine, and the development of alternatives to animal testing, with a strong emphasis on sustainability, innovation, and cross-disciplinary collaboration.
Organovo Inc. The company is engaged in the development of 3D bioprinted human tissues intended for the preparation of medical research and drug development. The company uses its proprietary bioprinting technology to create tissue models that replicate, in structure and function, human organs in vivo. These models are then used for studying disease, testing drug responses, and investigating future applications in regenerative medicine. The goals of Organovo provide more accurate and human-relevant alternatives in the place of traditional cell culture and animal testing.
Advanced Solutions Advanced Solutions Life Sciences (ASLS) is a company that builds integrated platforms which include hardware, software, and biological tools for 3D bio fabrication and tissue engineering. Their flagship system is a robotic platform that assembles biological structures using design software and specialized bio tools. Their focus is on providing solutions in areas such as drug discovery, regenerative medicine, high throughput assays, and human tissue modeling. Their facilities include engineering, biological research, manufacturing, and support to customers worldwide.
FluidForm Bio is a biotechnology company focused on developing advanced 3D bioprinting technologies to create living human tissues for therapeutic use. Their proprietary printing method allows the construction of complex, vascularized tissue structures by carefully placing cells and proteins in supportive gel environments. This technology helps overcome challenges like keeping cells alive and ensuring nutrients reach all parts of the tissue. One of their main goals is to develop implantable tissues that can treat diseases such as type 1 diabetes by restoring natural functions in the body.
Inventia Life Science It is an Australian biotech company that develops tools and platforms for creating complex three-dimensional cell culture models that mimic human tissue. Their core technology allows researchers to produce reproducible, disease-relevant 3D cell models in their own labs, helping in drug discovery and biological research. They focus on making workflows more accessible and reliable, blending novel bioinks with automated bioprinting devices. Their RASTRUM platform is a signature product that combines droplet-based deposition of cells and matrix to build physiologically meaningful 3D structures.
Hydrogels for 3D Bioprinting Industry News
The hydrogels for 3D bioprinting market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue (USD Million) and volume (Kilo Tons) from 2021 to 2034, for the following segments:
Click here to Buy Section of this Report
Market, By Hydrogel Type
Market, By Biotechnology Printing
Market, By Application
Market, By End Use
• Pharmaceutical Companies
• Biotechnology Companies
• Academic & Research Institutions
• Clinical & Healthcare Providers
• Other End Use
The above information is provided for the following regions and countries: